Asgard Therapeutics
Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy
25 employees · est. 2018 · Lund, Sweden
OncoResponse is the older company (2018 vs 2016); Asgard Therapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | Asgard Therapeutics | OncoResponse |
|---|---|---|
| Founded | ||
| Founded | 2018 | 2016 older |
| Headquarters | ||
| Headquarters | Lund, Sweden | Houston, United States |
| Employees | ||
| Employees | 25 larger | 10 |
| Industry | ||
| Industry | Biotechnology, Health and Wellness | Biopharma, Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Series A | Unknown |
| Total Funding | ||
| Total Funding | $36.00M | $117.10M |
| Funding Rounds | ||
| Funding Rounds | 3 | 6 |
| Services | ||
| Services | Not tracked yet | Development of novel cancer immunotherapies, Discovery of human antibodies, Partnering with collaborators in immuno-oncology, Preclinical studies |
| Target Customers | ||
| Target Customers | Not tracked yet | Biopharmaceutical companies, Oncology researchers, Cancer patients, Clinical study collaborators |
| Taxonomy | ||
| Taxonomy | Biotech, Cancer Immunotherapy, Cell Reprogramming, Gene Therapy, Immune Responses, Antigen Presenting Cells, Personalized Medicine, Biological Technology, Oncology, Start-up, Investor-backed, Lund University, TrojanDC Technology, Novo Holdings, Boehringer Ingelheim Venture Fund | Immuno-oncology, Biotech, Cancer Immunotherapy, Antibody Platform, B-cell Discovery, Tumor Microenvironment, Monoclonal Antibodies, Immune Activation, TME Immunosuppression, Elite Cancer Responders, Novel Therapeutics, Myeloid Biology, Clinical Trials, Human Antibodies |
| Website | ||
| Website | asgardthx.com | oncoresponse.com |
About Asgard Therapeutics
Asgard Therapeutics, a Swedish biotech company founded in 2018, is at the forefront of cancer immunotherapy research through direct cell reprogramming technologies. The company's proprietary TrojanDC technology, originating from Lund University, aims to initiate immune responses by leveraging profes...
About OncoResponse
OncoResponse, founded in 2016, is an innovative player in the immuno-oncology biotech sector. This biopharma company is particularly notable for its strategic collaboration with the MD Anderson Cancer Center, which amplifies its capabilities in treating cancer. Utilizing a proprietary B-cell discov...
We will tell you when either one moves
BounceWatch watches Asgard Therapeutics and OncoResponse for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Asgard Therapeutics and OncoResponse — by email.
Frequently Asked Questions
Compare Asgard Therapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Asgard Therapeutics on 11 Sep 2024, and OncoResponse on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.